Copenhagen, 2015-02-03 15:03 CET (GLOBE NEWSWIRE) -- Exiqon A/S. listed on Nasdaq OMX Copenhagen ( “EXQ”) hereby announces management’s and closely related parties’ transactions with shares and related securities in Exiqon A/S pursuant to section 28a of the Danish Securities Trading Act as follows:
| Type of transaction: | Buy |
| Type of security | Share |
| Date of trade: | 3 February 2015 |
| Place of transaction: | Nasdaq OMX Copenhagen |
| Security Code (ISIN-kode): | DK0060077758 |
| Name: | Erik Wallden |
| Reason for reporting: | Member of the Supervisory Board |
| Traded securities (no.): | 40,000 |
| Market value in DKK of traded securities: | 305,108.00 |
Additional information
Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)
About Exiqon (for the media)
Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for RNA analysis used by academia, biotech and pharmaceutical companies around the world to make ground breaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics develops novel molecular diagnostic tests for early detection of cancer and treatment selection for patients based on gene activity analysis, using the tools developed by Exiqon Life Sciences. Exiqon is listed on the NASDAQ in Copenhagen. For more information about us, please visit www.exiqon.com
